Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Beta Bionics Inc (BBNX)

Beta Bionics Inc (BBNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX PR Newswire - Thu Feb 19, 7:10PM CST

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are...

BBNX : 13.46 (-1.10%)
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference GlobeNewswire - Thu Feb 19, 3:05PM CST

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management...

BBNX : 13.46 (-1.10%)
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 GlobeNewswire - Tue Feb 17, 3:05PM CST

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results...

BBNX : 13.46 (-1.10%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Fri Feb 13, 9:18AM CST

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX PR Newswire - Thu Feb 12, 5:56PM CST

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are...

BBNX : 13.46 (-1.10%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Sat Feb 7, 9:53AM CST

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX PR Newswire - Thu Jan 29, 9:00AM CST

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised...

BBNX : 13.46 (-1.10%)
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Thu Jan 29, 7:53AM CST

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Sun Jan 25, 7:22PM CST

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 13.46 (-1.10%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX PR Newswire - Thu Jan 22, 6:29PM CST

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised...

BBNX : 13.46 (-1.10%)

Barchart Exclusives

As Meta and Nvidia Announce a Huge, Multi-Year Partnership, Which Is the Better Stock to Buy? Barchart - 12 minutes ago
With AI spending accelerating and Meta expanding its partnership with Nvidia, should investors back the chip king or the social media giant for long-term growth? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot